The immunoassay market is entering a period of steady expansion as healthcare systems increasingly prioritize early disease detection, biomarker analysis, personalized medicine, and rapid diagnostic testing. The market was valued at USD 28.0 billion in 2025 and is estimated to reach USD 29.3 billion in 2026, before growing to USD 40.3 billion by 2033. It is projected to expand at a 4.6% CAGR from 2026 to 2033. Rising demand for precision medicine and the growing burden of chronic and infectious diseases are supporting this expansion.

Download a free sample copy of the Immunoassay market report to understand detailed coverage and inclusions in the final report

Market Growth and Key Demand Drivers

Immunoassays are increasingly important for detecting diseases, analyzing biomarkers, monitoring therapies, and supporting treatment decisions. The rising prevalence of cancer, cardiovascular diseases, diabetes, autoimmune disorders, and infectious diseases is creating continued demand for sensitive and specific diagnostic solutions.

The shift from conventional one-size-fits-all treatment toward personalized medicine is particularly important for market development. Immunoassays can help identify biomarkers associated with treatment response, supporting more targeted therapeutic decisions. Pharmaceutical companies are also integrating immunoassays into drug development pipelines, further strengthening demand.

Market Dynamics and Technology Development

Automation is becoming an important part of immunoassay adoption. Automated analyzers can improve laboratory efficiency, throughput, and diagnostic precision, while high-throughput platforms enable healthcare providers to process larger volumes of samples.

Technology development is also broadening the capabilities of immunoassays. Multiplex assays, nanotechnology-based detection systems, biosensor integration, and AI-assisted diagnostic platforms are supporting simultaneous biomarker detection and faster interpretation. AI and machine learning are increasingly being applied to data interpretation, pattern recognition, predictive analytics, and laboratory workflow automation.

Cross-reactivity and false-positive results remain challenges. Structurally similar antigens or biomolecules can unintentionally bind with assay antibodies, potentially affecting diagnostic accuracy. In response, companies are focusing on advanced multiplex immunoassays, chemiluminescence immunoassays, and AI-integrated interpretation technologies designed to improve specificity and reliability.

Product and Application Landscape

Reagents and kits represented the leading product category, accounting for 66.2% of the market in 2025. Demand is being supported by the widespread use of ELISA kits, chemiluminescence immunoassays, lateral flow assays, and rapid antigen test kits across disease-specific diagnostic applications.

The software and services segment is projected to record the fastest CAGR during the forecast period. Growing adoption of automated diagnostic platforms, laboratory workflow management, AI-enabled analytics, cloud-based data management, assay optimization, and technical support is creating new opportunities around immunoassay systems.

In applications, infectious disease held the largest share at 30.1% in 2025 and is projected to grow at a 5.5% CAGR. Immunoassays are widely used for pathogen detection, screening, and disease monitoring. Oncology and autoimmune disease applications are also expected to expand as biomarker-based diagnostics and personalized treatment become increasingly important.

Technology and Specimen Insights

Enzyme immunoassays led the technology segment with a 64.1% revenue share in 2025. Their sensitivity, specificity, and compatibility with automated laboratory systems continue to support adoption across cancer diagnostics, cardiovascular testing, infectious disease detection, and personalized medicine.

Rapid tests are projected to grow rapidly as demand increases for portable and point-of-care diagnostic solutions. Microfluidics, nanotechnology, biosensors, electrochemiluminescence immunoassays, and other advanced technologies are contributing to faster and more accessible testing.

Blood accounted for the largest specimen share at 41.4% of revenue in 2025, while urine is projected to be the fastest-growing specimen segment.

Regional and End-use Outlook

North America dominated the market with a 47.3% revenue share in 2025, supported by healthcare infrastructure, chronic and infectious disease prevalence, biomarker-based testing, personalized medicine, and automated immunoassay adoption.

Asia Pacific is projected to register the fastest CAGR from 2026 to 2033. Healthcare infrastructure improvements, healthcare reforms, a large patient pool, and increasing chronic disease prevalence are supporting demand.

Hospitals represented the largest end-use category, accounting for 32.4% of revenue in 2025. Clinical laboratories are also expected to experience robust growth as demand rises for high-throughput testing, biomarker analysis, automated workflows, and AI-enabled laboratory analytics.

Competitive Landscape and Future Opportunities

The growing adoption of point-of-care diagnostics represents a significant opportunity. Portable immunoassay solutions for infectious disease detection, cardiac markers, pregnancy testing, and chronic disease monitoring can support more decentralized testing. Continued advances in rapid assays, microfluidics, digital immunoassays, automation, and AI are expected to shape the market's next phase of development.

FAQ

Which segment leads the immunoassay market?

Reagents and kits led the product segment with a 66.2% share in 2025, while infectious disease was the leading application with a 30.1% revenue share in 2025. Enzyme immunoassays led the technology segment with a 64.1% revenue share in 2025.

What trends are shaping the immunoassay market?

Automation, multiplex testing, point-of-care diagnostics, biomarker-based testing, AI-assisted interpretation, microfluidics, nanotechnology, personalized medicine, and rapid diagnostic platforms are among the major trends shaping market development.

Key Immunoassay Companies:

Abbott
Siemens Healthineers
Danaher Corporation (Beckman Coulter)
bioMérieux SA

Explore the full list of profiled companies operating in this market with recent strategic initiatives

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

How Biomarker Detection Is Reshaping the Next Phase of Immunoassay Growth

The global immunoassay market size was estimated at USD 28.0 billion in 2025 and is projected to grow from USD 29.3 billion in 2026 to USD 40.3 billion by 2033